Navigation Links
International Isotopes Inc. Announces Submission of the License Application for Their Uranium De-conversion and Fluorine Extraction Processing Facility

IDAHO FALLS, Idaho, Dec. 31 /PRNewswire-FirstCall/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces it has submitted its license application to the U. S. Nuclear Regulatory Commission (NRC) for its depleted uranium de-conversion and fluorine extraction processing facility.

Steve T. Laflin, President and CEO, stated, "The submission of this license application represents another significant accomplishment for the Company and is the most recent milestone in our continued progress towards construction of this unique, commercial, environmentally friendly nuclear facility. The project is on target and on schedule."

In March 2009, the Company announced the selection of a 640-acre building site for the facility just west of Hobbs, New Mexico. In June the Company announced completion of the Conceptual Design Report (CDR) for the project.

Laflin continued, "We are very pleased with the quality and pace of licensing and design work on this project by Company personnel and our licensing and engineering subcontractor, Advanced Process Technology Systems L.L.C. (APTS). APTS assembled an excellent team of personnel highly experienced in many important aspects of licensing, such as Integrated Safety Analysis. The extensive experience of that team has helped to produce a high quality license application document."

The NRC license review is expected to take approximately 18 to 24 months to complete. The Company plans to select a design and build contractor next year and may initiate some pre-license construction activities at the Hobbs site in 2010, subject to NRC approval. The project schedule envisages completion of construction by the end of 2012.

About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients.

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statements with respect to the quality of the license application, the time required for the NRC to complete the license application review and approval, plans for pre-license construction activities, and goals of constructing a depleted uranium de-conversion processing and fluorine extraction facility. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes Inc.'s filings with the Securities and Exchange Commission at, including our annual report on Form 10-K for the year ending December 31, 2008. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Additional factors that could materially affect the results, performance or achievements of the Company include the ability to successfully obtain additional funding necessary to complete its planned de-conversion facility. Achievement by the Company of the project is substantially dependent on success in securing off-take agreements with commercial enrichment companies for depleted uranium hexafluoride for de-conversion services and supply of the raw material for the production of high quality fluoride gasses. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, visit our web site at

    For More Information, Contact:
    Steve Laflin, President and CEO
    (208) 524-5300

    For More Information, Contact:
    Steve Laflin, President and CEO
    (208) 524-5300

SOURCE International Isotopes Inc.



SOURCE International Isotopes Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
2. AHD International & Funktional Beverages, Inc Launch Red Stuff™ with LuraLean
3. American University of Antigua Becomes First International School to Administer Web-Based NBME Exam
4. Jamie Oliver, Chef and International Nutrition Advocate, Named Recipient of 2010 TED Prize
5. Reliv Internationals Carl W. Hastings Elected to Board of the Council for Responsible Nutrition
6. Orameds Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
7. Air Ambulance Company AirMed International Partners with ECMO Advantage for Life-Saving Transports
8. Mindray Medical International Limited Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
9. Service Corporation International Extends Offer for Keystone North America Inc.
10. The Garlands of Barrington Earns International Recognition, Residents Reap the Benefits of Award-Winning EngAGE Lifestyle
11. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... ... 27, 2015 , ... CBD College is proud to announce that ... awarded accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join ... twelve colleges and universities in the state of California make the cut. CBD College ...
(Date:11/27/2015)... Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... meeting. They observed that both STEMI and Sepsis conditions present in similar ways and ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 Research and Markets ... "Global Intrauterine Devices Market 2015-2019" report to ... --> In this report, the author the present ... market for 2015-2019. To calculate the market size, the ... type of products: Hormonal IUDs and copper IUDs. The ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology: